Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Aerobic gram-negative bacteria are a diverse group of rod-shaped or spherical prokaryotes that require oxygen for growth. They possess an inner cytoplasmic membrane, a thin peptidoglycan layer, and an outer membrane containing lipopolysaccharide endotoxins. This unique envelope structure confers increased resistance to many antibiotics compared with gram-positive organisms. Clinically important genera include Neisseria (N. gonorrhoeae, N. meningitidis), Moraxella (M. catarrhalis), Escherichia (E. coli), Klebsiella (K. pneumoniae), Pseudomonas (P. aeruginosa), Salmonella (S. enterica) among others. These bacteria can cause serious infections such as pneumonia, urinary tract infections, sepsis, meningitis, gastroenteritis and more—often with high morbidity due to their ability to evade host defenses via their capsule and outer membrane structures. Because "aerobic gram-negative bacterium" refers broadly to any member of this category rather than one defined molecule or protein target used in drug discovery/therapeutics research contexts—and because it encompasses hundreds of different species—it should not be considered an appropriate entry for structured therapeutic targeting databases. "Aerobic gram‐negative cocci are sphere‐shaped bacteria that require oxygen... Pathogenic strains can cause gastrointestinal inflammation... kidney damage... Different strains can cause salmonellosis... diarrhea... typhoid fever." "Gram‐negative bacteria have an inner cell membrane ... thin peptidoglycan layer ... outer membrane containing lipopolysaccharides ... Porins exist in the outer membrane..." "Gram‐negative bacterial infections include ... gastroenteritis ... pneumonia ... peritonitis ... urinary tract infections … bloodstream infections … wound or surgical site infections … meningitis." If you need information about a specific genus/species within aerobic gram-negative bacteria—or about particular molecular targets found within these organisms—please specify further so I can provide more targeted data!
Drugs act by: Inhibiting cell wall synthesis (e.g., beta-lactams); Disrupting protein synthesis (e.g., aminoglycosides); Inhibiting DNA gyrase/topoisomerase IV (e.g., fluoroquinolones); Disrupting outer membrane integrity (e.g., polymyxins). (Mechanisms depend on drug class and specific bacterial targets.)
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Aerobic Gram-negative bacterium.